Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals

Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals

The U.S. Food and Drug Administration approved in late December Ionis Pharmaceuticals Inc's (NASDAQ: IONS) therapy for the treatment of spinal muscular atrophy called Spinraza.

In a research report on Friday, Jefferies' Eun Yang suggested that Spinraza is Ionis' only exciting product in its pipeline. Accordingly, the analyst maintained an Underperform rating on Ionis' stock with a $17 price target.

Here is what the analyst has to say on Ionis' other products in its pipeline.


Volanesorsen is an antisense drug in development for two rare metabolic disorders: FCS and FPL.

The analyst sees limited market potential for the therapy at $130 million which is similar to Juxtapid with approximately $79 million in the first nine months of 2016.


IONIS-GCGRRx is an antisense drug designed to reduce the production of glucagon receptors, or GCGR, to treat patients with type 2 diabetes

The analyst questioned what therapeutics merits the therapy offers patients in the already crowded market.


FXIRx is an antisense drug designed to reduce the production of Factor XI. Factor XI is a clotting factor produced in the liver that's an important component of the coagulation pathway.

The analyst noted that recent studies found that the therapy showed no clinically meaningful reduction in platelets nor any reported tx-SAEs


IONIS-DMPK-2.5Rx is an antisense drug designed to reduce the toxic dystrophia myotonica-protein kinase, or DMPK, RNA to treat patients with Myotonic Dystrophy Type 1 (DM1).

The analyst pointed out that the program has been discontinued due to inadequate potency in muscle tissue. Ionis and its partner Biogen Inc (NASDAQ: BIIB) will now develop a muscle-targeting LICA alternative.

Latest Ratings for IONS

Apr 2019Initiates Coverage OnNeutral
Mar 2019MaintainsNeutralNeutral
Feb 2019MaintainsOutperformOutperform

View More Analyst Ratings for IONS
View the Latest Analyst Ratings

Posted-In: Eun Yang Ionis JefferiesAnalyst Color Health Care FDA Analyst Ratings General Best of Benzinga


Related Articles (BIIB + IONS)

View Comments and Join the Discussion!

Latest Ratings

RTLRInitiates Coverage On
RTLRInitiates Coverage On
DBVTInitiates Coverage On14.0
RTLRInitiates Coverage On22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Lean Hog Futures Move Down

The Gap Delivers December Sales Upside Surprise